In research conducted in mice, scientists identified a trio of existing medicines as promising candidates for treating a rare and severe form of infant leukemia caused by a genetic changed called KMT2A::AFF1
Prospective study published in Clinical Cancer Research shows that women >70 who tested Signatera MRD-negative could avoid surgery and remain progression-free
Drug Discovery USA 2026 to focus on emerging multifunctional small molecule and biologic approaches to drug difficult targets
Collaboration aims to discover and develop antibodies against multiple therapeutic targets designated by Merck
The U.S. FDA has cleared the Investigational New Drug (IND) application for ABSK061, a highly selective small-molecule FGFR2/3 inhibitor, for the treatment of children with achondroplasia (ACH)
Prospective UT MD Anderson study shows RNA analysis expands on treatment options beyond DNA testing
The treatment preserved quality of life
IDE approval by the FDA expands global trial to the United States as first study participant is treated in the United Kingdom
Co-occurrence of myocarditis with myositis and myasthenia gravis may also increase risk of death
Data presented at the AACR 2026 revealed a 44% reduction and growing urban concentration of U.S. phase I NSCLC trial sites between 2020 and 2024
This approach may eventually help guide personalized treatment decisions for patients diagnosed with these cancers
All patients were negative for minimal residual disease, and no patients experienced progression to active multiple myeloma during the median 15.3 months of follow-up
National Institutes of Health awards The Research OutSmarts Endometriosis team an $850,000 prize over one year to accelerate the development of a non-invasive diagnostic test
A biology-guided artificial intelligence model applied to routine pathology slides accurately predicted outcomes and response to immunotherapy in patients with metastatic NSCLC
The AACR will present the 2026 AACR Award for Lifetime Achievement in Cancer Research to Dr. James P. Allison, Fellow of the AACR Academy, during the AACR Annual Meeting 2026
The investigational drug led to objective response and disease control in patients with late-stage disease
The AACR will present the 2026 AACR-Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research during the AACR Annual Meeting 2026
Responses were seen in patients who were not treated with prior KRAS G12C inhibitors as well as those whose disease progressed on prior KRAS G12C inhibitors
An updated trial analysis presented at AACR 2026 showed that the investigational KRAS G12D inhibitor zoldonrasib demonstrated clinical activity with a favorable safety profile in previously treated KRAS G12D‑mutant NSCLC patients
Extended immunotherapy showed manageable long‑term safety in adolescents and young adults with alveolar soft part sarcoma, according to phase II data presented at AACR 2026
The AACR will honor leaders from government and the advocacy community with awards for distinguished service in support of cancer research at the AACR Annual Meeting 2026
Comprehensive analysis of one of the largest datasets with harmonized variant calls from over 8,000 cancer whole genomes enables researchers worldwide to uncover rare drivers, new targets, and AI-ready insights that could reshape precision oncology
Development of novel Ankyrons will enable study of emerging high-consequence infectious diseases to inform vaccines and treatments
Collaboration to enable more streamlined end-to-end workflows while maintaining sample integrity
Minimally invasive blood test enables greater patient access to monitoring of neuroinflammatory status versus current standard of care methods
